Selexipag (ACT-293987, NS-304) - Analysis and Forecasts from 2015 to 2020

Selexipag (ACT-293987, NS-304) - Analysis and Forecasts from 2015 to 2020

Summary

GlobalData’s pharmaceuticals report, “Selexipag (ACT-293987, NS-304) - Analysis and Forecasts from 2015 to 2020” provides Selexipag sales estimates for US, EU5 and Japan. In addition, it covers detailed clinical assessment of the drug, factors impacting drug sales, competitive landscape, and analysis of sales performance during the forecast period (2015-2020). The report also includes information on Pulmonary Arterial Hypertension market. This report is built using data and information sourced from GlobalData’s proprietary databases, primary and secondary research using Company’s corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together with in-house analysis, by GlobalData's team of industry experts.

Scope

- Therapy area profile including patient population for the US, EU5 and Japan (seven major markets)
- Analysis and review of Selexipag including sales data
- Qualitative and quantitative assessment of market space
- Analysis of the trends, drivers and restraints shaping and defining the markets
- In-depth analysis of Selexipag including efficacy, safety, pricing, competition and other details which influence its sales potential
- Detailed sales forecast for 2015-2020 for Selexipag in the seven major markets

Reasons to buy

- Understand and capitalize by identifying products that are most likely to ensure a robust return
- Stay ahead of competition by understanding the changing competitive landscape
- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
- Make more informed business decisions from insightful and in-depth analysis of the drug’s performance
- Examine the historical sales performance of a drug in seven major markets
- Obtain sales forecast for currently marketed/pipeline drug for 2011-2020 for all seven major markets SHOW LESS READ MORE >

1
1

1.1 List of Tables
1.2 List of Figures
2 Introduction
2.1 Pulmonary Arterial Hypertension
2.2 Epidemiology
2.2.1 Prevalence
2.2.2 Mortality
2.3 Etiology
2.3.1 Scleroderma
2.3.2 Sickle Cell Disease
2.3.3 HIV/AIDS
2.3.4 Drug Abuse and Toxins
2.4 Economic Impact of PAH
2.5 GlobalData Report Guidance
3 Pulmonary Arterial Hypertension (PAH): Market Characterization
3.1 PAH Market
3.2 PAH Market Forecasts and CAGR
3.3 PAH Market : Drivers and Restraints
3.3.1 Drivers
3.3.2 Barriers
4 Classification of PAH
4.1 Classification Based on Cause and Clinical Presentation
4.1.1 Idiopathic PAH
4.1.2 Familial PAH
4.1.3 Drug Induced PAH
4.1.4 PAH Associated with Other Conditions
4.1.5 PAH Associated with Significant Venous or Capillary Involvement
4.2 Symptomatic Profile of PAH
5 Evolution of PAH Treatments
6 Medications
6.1 Prostanoids
6.1.1 Epoprostenol
6.1.2 Treprostinil
6.1.3 Iloprost
6.1.4 Beraprost
6.2 Endothelin Receptor Antagonists
6.2.1 Bosentan
6.2.2 Ambrisentan
6.2.3 Sitaxsentan
6.3 Phosphodiesterase Type 5 Inhibitors
6.3.1 Sildenafil
6.3.2 Tadalafil
6.4 Surgical Treatments
6.5 Investigational Combination Regimens
6.6 New Targets for PAH Therapy
7 Market Share by Class in PAH
8 Selexipag
8.1 Introduction
8.2 Mechanism of Action
8.3 Clinical Studies
8.3.1 Phase II
8.3.2 Phase III- GRIPHON
8.4 Milestones of Selexipag
8.5 Factors Affecting Sales of Selexipag
8.5.1 First in Class Drug
8.5.2 Dosing Compliance
8.5.3 Availability of Generics
8.6 Actelion / Nippon Shinyaku Alliance
8.7 Drug Evaluation
8.7.1 Drug Risk Benefit Score
8.7.2 Intensity of Competition
8.8 Sales Estimates
8.8.1 Target Patient Pool for Selexipag
8.8.2 Dosing
8.8.3 Market Penetration
8.8.4 Annual Cost of Therapy
8.8.5 Sales Projections of Selexipag
9 PAH Market: Appendix
9.1 Market Definitions
9.2 List of Abberiviations
9.3 Research Methodology
9.3.1 Coverage
9.3.2 Secondary Research
9.3.3 Forecasting
9.3.4 Number of Patients Approved to take the Drug
9.3.5 Net Penetration of Drug
9.3.6 Net Annual Dosing
9.3.7 Annual Cost of Therapy
9.3.8 Primary Research
9.3.9 Expert Panels
9.4 Drug Sales Estimates Model
9.5 Contact Us
9.6 Disclaimer
9.7 Sources

1.1 List of Tables
Table 1: PAH, Global, Major Marketed Drugs
Table 2: PAH, Global, Pipeline (Phase III)
Table 3: PAH Drugs Evolution
Table 4: Milestones of Selexipag
Table 5: Drug Risk Benefit Score of Selexipag
Table 6: Safety and Tolerability of Selexipag in Comparison with Placebo
Table 7: Annual Cost of Therapy of Selexipag, 2015
Table 8: Selexipag, PAH, Global, Sales Forecasts ($m), 2015-2020
Table 9: Selexipag, PAH, The US, Sales Forecasts ($m), 2015–2020
Table 10: Selexipag, PAH, The UK, Sales Forecasts ($m), 2015–2020
Table 11: Selexipag, PAH, France, Sales Forecasts ($m), 2015–2020
Table 12: Selexipag, PAH, Germany, Sales Forecasts ($m), 2015–2020
Table 13: Selexipag, PAH, Italy, Sales Forecasts ($m), 2015–2020
Table 14: Selexipag, PAH, Spain, Sales Forecasts ($m), 2015–2020
Table 15: Selexipag, PAH, Japan, Sales Forecasts ($m), 2017-2020

1.2 List of Figures
Figure 1: PAH, Global, Market Size Forecasts ($bn), 2010–2020
Figure 2: PAH, Worldwide, Market Share by Class (%), 2010
Figure 3: Drug Model Diagram of Selexipag
Figure 4: Selexipag, PAH, Global, Sales Forecasts ($m), 2015-2020
Figure 5: Selexipag, PAH, The US, Sales Forecasts ($m), 2015–2020
Figure 6: Selexipag, PAH, The UK, Sales Forecasts ($m), 2015–2020
Figure 7: Selexipag, PAH, France, Sales Forecasts ($m), 2015–2020
Figure 8: Selexipag, PAH, Germany, Sales Forecasts ($m), 2015–2020
Figure 9: Selexipag, PAH, Italy, Sales Forecasts ($m), 2015–2020
Figure 10: Selexipag, PAH, Spain, Sales Forecasts ($m), 2015–2020
Figure 11: Selexipag, PAH, Japan, Sales Forecasts ($m), 2017-2020
Figure 12: Selexipag, PAH, Global, Sales Distribution by Country (%), 2020
Figure 13: Drug Model Diagram
Figure 14: Patients Approved for the Drug